CLICK HERE FOR BRIUMVI^® (ublituximab-xiiy) PRESCRIBING INFORMATION

A Bold
Approach

VIDEO: Updated Results of the Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients (pts) with B-cell Malignancies

Started August 31, 2021 255

Read more

Updated Results of the Selective Bruton Tyrosine kinase (BTK) Inhibitor TG-1701, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients (pts) with B-cell Malignancies

Started June 18, 2021 271

Read more

Antitumoral Activity of the Novel BTK Inhibitor TG-1701 is Associated with Disruption of Ikaros Signaling and Improvement of Anti-CD20 Therapy in B-cell Non-Hodgkin Lymphoma

Started June 18, 2021 243

Read more

Updated Results of the Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients (pts) with B-cell Malignancies

Started June 11, 2021 238

Read more

Updated Results of the Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701, as Monotherapy and in Combination with Ublituximab and Umbralisib(U2) in Patients (pts) with B-cell Malignancies

Started June 4, 2021 404

Read more

VIDEO: Clinical Activity of TG-1701, As Monotherapy and in Combination with Ublituximab and Umbralisib (U2), in Patients with B-Cell Malignancies

Started April 15, 2021 246

Read more

VIDEO: A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Started April 15, 2021 291

Read more

VIDEO: Umbralisib, a PI3Kδ/CK1ε dual inhibitor demonstrates marked clinical activity in patients with relapsed or refractory indolent non-Hodgkin lymphoma: Results from the Phase 2 global UNITY-NHL trial

Started April 15, 2021 587

Read more

VIDEO: Phase 3 Study of Umbralisib Combined With Ublituximab vs Obinutuzumab Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia: Results From UNITY-CLL

Started April 15, 2021 317

Read more

Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients with Relapsed/Refractory Indolent Lymphoma

Started March 9, 2021 1182

Read more

A Phase 3, Randomized Trial of Ublituximab Plus Ibrutinib for Patients with Relapsed/Refractory High-Risk Chronic Lymphocytic Leukaemia

Started February 23, 2021 320

Read more

Phase 3 Study of Umbralisib Combined With Ublituximab vs Obinutuzumab Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia: Results From UNITY-CLL

Started December 7, 2020 484

Read more